Wide Ranks

IFRX

InflaRx N.V.

2.40

Top Statistics
Market Cap 141 M Forward PE -2.21 Revenue Growth 0.00 %
Current Ratio 8.91 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.78 Enterprise / Revenue 670.82 Price To Sales Trailing12 Months 1339.74
Profitability
Profit Margins 0.00 % Operating Margins -242200.12 %
Balance Sheet
Total Cash 19 M Total Cash Per Share 0.3250 Total Debt 998670
Total Debt To Equity 1.22 Current Ratio 8.91 Book Value Per Share 1.74
All Measures
Short Ratio 517.00 % Message Board Id finmb_42434000 Shares Short Prior Month 161056
Return On Equity -0.4534 City Jena Uuid d7dac691-49fb-3198-8a3e-7fa9a0420fa3
Previous Close 2.20 First Trade Date Epoch Utc 1 B Book Value 1.74
Beta 1.58 Total Debt 998670 Volume 376180
Price To Book 1.38 Fifty Two Week Low 1.17 Total Cash Per Share 0.3250
Total Revenue 105483 Shares Short Previous Month Date 1 B Target Median Price 7.04
Max Age 86400 Recommendation Mean 1.60 Sand P52 Week Change 0.3133
Operating Margins -242200.12 % Target Mean Price 7.74 Net Income To Common -46884544
Short Percent Of Float 0.0044 Implied Shares Outstanding 58 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 603600 Average Volume10days 603600
Total Cash 19 M Next Fiscal Year End 1 B Revenue Per Share 0.0020
Held Percent Insiders 0.0734 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 2.20 Target Low Price 4.74
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.64 Open 2.17
Free Cashflow -2124254 Dividend Yield 0.00 % Return On Assets -0.2198
Time Zone Short Name EST Trailing Eps -1.03 Day Low 2.17
Address1 Winzerlaer Str. 2 Shares Outstanding 58 M Price Hint 4
Target High Price 12.12 Website https://www.inflarx.de 52 Week Change 0.7778
Average Volume 160920 Forward Eps -1.06 Recommendation Key buy
Quick Ratio 204.60 % Is_sp_500 False Regular Market Day High 2.44
Profit Margins 0.00 % Debt To Equity 1.22 Fifty Two Week High 2.44
Day High 2.44 Shares Short 241704 Regular Market Open 2.17
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 670.82
Revenue Growth 0.00 % Shares Percent Shares Out 0.0041 Operating Cashflow -43129960
Currency USD Time Zone Full Name America/New_York Market Cap 141 M
Is_nasdaq_100 False Zip 07745 Quote Type EQUITY
Industry Biotechnology Long Name InflaRx N.V. Regular Market Day Low 2.17
Held Percent Institutions 0.2252 Current Price 2.40 Enterprise To Ebitda -1.78
Financial Currency EUR Current Ratio 8.91 Industry Disp Biotechnology
Number Of Analyst Opinions 4 Country Germany Float Shares 48 M
Two Hundred Day Average 1.55 Enterprise Value 70 M Price To Sales Trailing12 Months 1339.74
Forward PE -2.21 Regular Market Volume 376180 Ebitda -39669256
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
InflaRx N.

V.

, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.

The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases.

Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS.

It has co-development agreement with Beijing Defengrei Biotechnology Co.

Ltd.

; and clinical trial collaboration and supply agreement with Merck & Co.

Inc. The company was formerly known as Fireman B.

V.

and changed its name to InflaRx N.

V.

in 2017.

InflaRx N.

V.

was founded in 2007 and is headquartered in Jena, Germany.